Gingival hyperplasia is an abnormal overgrowth of gum tissue that can partially or even completely cover your teeth. It ranges from mild thickening of the gum line to severe enlargement that interferes with chewing, speaking, and oral hygiene. The condition is most commonly triggered by certain medications, but hormonal changes, genetic factors, and chronic inflammation can also cause it.
What Happens Inside the Gums
Gingival hyperplasia involves two problems happening at the same time: your gum tissue produces too much structural material, and it breaks down less of it than normal. The cells responsible for building connective tissue, called fibroblasts, become overactive. They produce excess collagen and other structural proteins that make up the scaffolding of your gums. At the same time, the normal recycling process that clears away old collagen slows down. The result is a net buildup of dense, fibrous tissue.
Inflammation plays an amplifying role. When plaque and bacteria irritate the gums, the body sends immune cells to the area, which in turn stimulate even more fibroblast activity. This creates a cycle: the overgrown tissue makes it harder to clean your teeth, which leads to more plaque buildup, which drives more inflammation, which fuels further overgrowth. Growth factors, particularly one called TGF-beta, ramp up the production of fibrous material and encourage fibroblasts to multiply faster than usual.
Medications That Cause It
Three classes of drugs are responsible for the vast majority of cases. Anticonvulsants (seizure medications), calcium channel blockers (used for high blood pressure and heart conditions), and immunosuppressants (used after organ transplants) all share the ability to disrupt collagen turnover in gum tissue, though through slightly different pathways.
Phenytoin, one of the oldest and most widely prescribed seizure medications, is the most well-known trigger. About 50% of people on long-term phenytoin therapy develop some degree of gum overgrowth, with reported rates ranging from 3% to 93% depending on the study and how overgrowth is measured. Other anticonvulsants like valproic acid, carbamazepine, and phenobarbital have been linked to the condition, though far less frequently.
Among calcium channel blockers, nifedipine carries the highest risk. In one controlled study, about 34% of nifedipine users showed gingival enlargement compared to just 4% of people not taking the drug. Patients with higher nifedipine exposure had roughly 17 times the odds of developing overgrowth compared to controls. Amlodipine, diltiazem, verapamil, and felodipine have also been implicated.
Cyclosporine, an immunosuppressant commonly prescribed after organ transplantation, is the primary culprit in that drug class. Tacrolimus, sometimes used as an alternative, appears to carry a lower risk of gum overgrowth. Sirolimus has also been associated with the condition, though typically at levels that aren’t clinically significant.
Why Not Everyone on These Drugs Is Affected
Genetics determine how sensitive your fibroblasts are to these medications. Some people have fibroblast populations that respond aggressively to the drug by producing large amounts of collagen and slowing its breakdown. Others taking the same medication at the same dose may have no gum changes at all. Pre-existing gum inflammation acts as a strong predisposing factor, which is why meticulous oral hygiene can reduce, though not always prevent, the severity of overgrowth.
Non-Drug Causes
Hormonal shifts during pregnancy can trigger gum enlargement, particularly in the second and third trimesters when estrogen and progesterone levels peak. These hormones affect blood vessel growth in the gums, alter the immune response to plaque bacteria, and change the composition of the microbial community in the mouth. The overgrowth is typically most pronounced in areas where plaque is already present and often resolves after delivery.
Puberty can produce similar changes for the same reasons, as rising sex hormone levels temporarily make gum tissue more reactive to local irritants.
Hereditary gingival fibromatosis is a rare genetic condition where gum overgrowth occurs without any medication or hormonal trigger. The tissue is pink, firm, and densely stippled, with no signs of inflammation. It can appear on its own or as part of a broader genetic syndrome, and it follows an autosomal dominant inheritance pattern, meaning a child has a 50% chance of inheriting it if one parent carries the gene. In severe cases, the overgrown tissue can completely cover the teeth and even prevent them from erupting. Because of the high genetic variability involved, genetic testing to confirm the diagnosis is generally not considered worthwhile.
What It Looks and Feels Like
In mild cases, you may notice that the small triangular points of gum tissue between your teeth (the papillae) look blunted or rounded instead of sharp. As the condition progresses, these areas thicken and start creeping up over the tooth surface. In moderate cases, less than half the visible tooth is covered. In severe cases, more than half the tooth disappears under a mound of firm, pink tissue.
The overgrowth usually starts in the front of the mouth and is more prominent on the side facing the lips than the tongue. It can feel firm and rubbery, and it typically doesn’t bleed much unless there’s significant inflammation underneath. The enlarged tissue creates deep pockets between the gums and teeth that trap food and bacteria, leading to bad breath, tenderness, and an increased risk of tooth decay and periodontal disease.
How Severity Is Measured
Dentists and periodontists use grading scales that assess both how thick the tissue has become and how far it extends over the tooth crown. A commonly used system grades the vertical component on a four-point scale: grade 0 is normal gum tissue, grade 1 is mild blunting of the gum margin, grade 2 means less than half the tooth crown is covered, and grade 3 means more than half is buried. The horizontal component measures how much the gum has thickened outward, from normal to more than 2 millimeters beyond its usual boundary. These measurements help track whether the overgrowth is getting worse and guide treatment decisions.
Nonsurgical Treatment Options
The first line of management is improving oral hygiene and reducing inflammation. Professional cleaning, including scaling below the gum line, can shrink mild overgrowth by removing the inflammatory trigger. For people taking a causative medication, meticulous daily brushing and flossing may slow or limit the progression. However, professional cleaning alone often does not return the gums to their normal shape, particularly in moderate or severe cases. The residual overgrowth can make it nearly impossible to keep the area clean, creating a frustrating loop.
If a medication is responsible, the most logical step is switching to a drug that doesn’t affect gum tissue. In practice, this is often more complicated than it sounds. Neurologists may be reluctant to change a seizure medication that’s effectively controlling epilepsy, since finding the right anticonvulsant dose is a lengthy process with real risks. Transplant patients on cyclosporine face similar challenges, as the stakes of adjusting immunosuppression are high. When a medication switch is possible and the underlying cause is removed, some degree of spontaneous regression typically follows over several months, though the tissue may not fully return to normal.
When Surgery Is Needed
When overgrowth is moderate to severe, or when nonsurgical approaches haven’t restored a maintainable gum contour, surgical recontouring becomes necessary. Two procedures are commonly performed together. A gingivectomy removes the excess or diseased tissue, while a gingivoplasty reshapes the remaining gum into a natural, functional contour. These are often done in a single session.
Gingivectomy is typically recommended when the overgrowth is interfering with function, trapping bacteria in deep pockets, or creating cosmetic concerns. The procedure can be done with a scalpel, laser, or electrosurgery. Recovery involves some soreness and dietary restrictions for a week or two, but most people return to normal activities quickly.
The critical factor in long-term success is how thoroughly the tissue is removed. Complete excision with adequate margins produces a recurrence rate of about 8%, while incomplete or superficial removal leads to recurrence roughly 42% of the time. Overall, the pooled recurrence rate across studies is around 7%, with most recurrences appearing within the first six months after surgery. The average time to recurrence is about seven months, though it can happen as early as three weeks or as late as five years. If the causative medication is still being taken, recurrence is significantly more likely regardless of surgical technique.
Preventing Overgrowth
If you’re starting a medication known to cause gingival hyperplasia, the single most effective preventive measure is rigorous plaque control from day one. That means thorough brushing twice daily, daily flossing, and regular professional cleanings, ideally every three to four months rather than the standard six. Keeping inflammation as low as possible removes the co-factor that allows the drug to trigger fibroblast overgrowth. This won’t guarantee you’ll avoid the condition entirely, especially if your fibroblasts are genetically susceptible, but it meaningfully reduces both the likelihood and severity.